Botulinum Toxin Type A (BOTOX) for Treatment of Migraine

An open-label study and 2 double-blind, placebo controlled studies have provided supporting evidence of botulinum toxin type A (BTX-A) as an effective, well-tolerated treatment for migraine. Observed durations of benefit were consistent with known properties of BTX-A. Findings suggest that response may vary by features of preinjection headaches, such as migraine frequency. The precise mechanism by which BTX-A provides pain relief is hypothesized to be related not only to acetylcholine inhibition but also to a blocking action on the parasympathetic nervous system. Additional studies that control factors likely to be related to response may lead to better understanding of the BTX-A effect on migraine and an optimal treatment protocol.

An open-label study and 2 double-blind, placebo controlled studies have provided supporting evidence of botulinum toxin type A (BTX-A) as an effective, well-tolerated treatment for migraine.

Purchase this article:

PURCHASE FOR $25

For unlimited access to all issues and articles:

If you do not subscribe to Seminars in Cutaneous Medicine and Surgery, you may purchase instant access for your personal use. Terms and conditions will apply (see Copyright & Terms of Use). If you need assistance, contact Susan Hite ([email protected]).